EUVIMEDEUVIMED entdecken
Crossref

Interpreting the totality of clinical study data: is there a better way? Statistical methodology for quantitatively interpreting clinical study data across efficacy endpoints

Diana S Meske, Robert H Dworkin, Jeffrey Gudin, Mark Jaros, Kip Vought, Sarah Horine, Dmitri Lissin, Benjamin Vaughn

Contemporary Clinical Trials · 2026-11 · 170 · 108452

DOI: 10.1016/j.cct.2026.108452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026-11. Verfasst von Diana S Meske und 7 weiteren Autor:innen. Beteiligte Einrichtung: Alivio Clinical Consulting, Chicago, IL, USA; Clinical Development, Medical Affairs, and Regulatory Affairs, Consultants to Scilex Holding Company, P…. Hauptthemen laut MEDLINE: Endpoint Determination, Low Back Pain, Analgesics. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Interpretation of the efficacy of an intervention in clinical trials often relies on whether the p-value for the primary endpoint is

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endpoint DeterminationLow Back PainAnalgesicsHumansData Interpretation, StatisticalResearch DesignStatistics, NonparametricClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

AnalgesicClinical trial results interpretationDexamethasoneEpidural steroidLumbosacral radicular painStatistics for clinical trials

Substanzen

Analgesics

Autor:innen und Institutionen

  • Alivio Clinical Consulting, Chicago, IL, USA; Clinical Development, Medical Affairs, and Regulatory Affairs, Consultants to Scilex Holding Company, Palo Alto, CA, USA. Electronic address: dsmeske@gmail.com.
  • Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
  • Department of Anesthesiology and Pain Management, University of Miami Miller School of Medicine, USA.
  • Summit Analytical LLC, Denver, CO, USA.
  • Clinical Development, Medical Affairs, and Regulatory Affairs, Consultants to Scilex Holding Company, Palo Alto, CA, USA.
  • Clinical Development, Scilex Holding Company, Palo Alto, CA, USA.

Zitieren

APA

Meske, D. S., Dworkin, R. H., Gudin, J., Jaros, M., Vought, K., Horine, S., Lissin, D., & Vaughn, B. (2026). Interpreting the totality of clinical study data: is there a better way? Statistical methodology for quantitatively interpreting clinical study data across efficacy endpoints. Contemporary Clinical Trials, 170, 108452. https://doi.org/10.1016/j.cct.2026.108452

Vancouver

Meske DS, Dworkin RH, Gudin J, Jaros M, Vought K, Horine S, et al. Interpreting the totality of clinical study data: is there a better way? Statistical methodology for quantitatively interpreting clinical study data across efficacy endpoints. Contemporary Clinical Trials. 2026;170:108452. doi:10.1016/j.cct.2026.108452

BibTeX
@article{Meske2026,
  author = {Meske, Diana S and Dworkin, Robert H and Gudin, Jeffrey and Jaros, Mark and Vought, Kip and Horine, Sarah and Lissin, Dmitri and Vaughn, Benjamin},
  title = {Interpreting the totality of clinical study data: is there a better way? Statistical methodology for quantitatively interpreting clinical study data across efficacy endpoints},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  volume = {170},
  pages = {108452},
  doi = {10.1016/j.cct.2026.108452}
}
Kostenlos starten →